Analytical characterisation of an AAV9 gene therapy

被引：0
|
作者：
Perez, S. [1 ]
Bagnati, M. [1 ]
Gamlen, T. [2 ]
Yang, Z. L. [2 ]
Marginean, D. [1 ]
Rossi, F. [1 ]
Thompson, S. [1 ]
O'Grady, C. [1 ]
Li, L. [1 ]
Hautbergue, G. M. [3 ]
Azzouz, M. [2 ,3 ]
Barreira, M. [1 ]
机构：
[1] Cell & Gene Therapy Catapult, London, England
[2] Univ Sheffield, Gene Therapy Mfg & Innovat Ctr GTIMC, Sheffield, S Yorkshire, England
[3] Univ Sheffield, Sheffield Inst Translat Neurosci SITraN, Dept Neurosci, Sheffield, S Yorkshire, England
来源：
HUMAN GENE THERAPY | 2024年 / 35卷 / 3-4期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P112
引用
收藏
页码：A85 / A85
页数：1
相关论文
共 50 条
  • [31] Impacts of Pre-Existing Antibodies on Transduction Efficiency of Systemic AAV9 Gene Delivery: Potential for Broader Patient Eligibility for AAV Gene Therapy
    Meadows, Aaron S.
    Pineda, Ricardo
    Fu, Haiyan
    MOLECULAR THERAPY, 2018, 26 (05) : 102 - 103
  • [32] Endothelial retargeting of AAV9 in vivo
    Bozoglu, T.
    Lee, S.
    Ziegler, T.
    Kupatt, C.
    EUROPEAN HEART JOURNAL, 2022, 43 : 3090 - 3090
  • [33] Prevalence of Neutralizing Antibodies Against AAV2 and AAV9 Capsids in Propionic Acidemia (PA): Implications for Systemic Gene Therapy
    Hall, Camryn S.
    Sloan, Jennifer L.
    Galarreta, Carolina I.
    Shchelochkov, Oleg
    Manoli, Irini
    Venditti, Charles P.
    MOLECULAR THERAPY, 2024, 32 (04) : 298 - 298
  • [34] Directed Evolution of AAV1, AAV5 and AAV9 Variants for Efficient Gene Delivery to Eye
    Pendse, Nachiket
    Magdaleno, Eduardo
    Luna, Fabio
    Ge, Tan
    Hintzen, Steph
    Hill, Jake
    Mcelroy, Cameron
    Chen, Jayson
    Tam, Lawrence
    Hudry, Eloise
    Booler, Helen
    Stoner, Kirsten
    Penraat, Kelley
    Hedgeland, Mark
    Babaria, Shraddha
    Walker, John
    Ellis, Scott
    Ozsolak, Fatih
    MOLECULAR THERAPY, 2024, 32 (04) : 479 - 479
  • [35] Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation
    Chen, Xin
    Snanoudj-Verber, Sarah
    Pollard, Laura
    Hu, Yuhui
    Cathey, Sara S.
    Tikkanen, Ritva
    Gray, Steven J.
    MOLECULAR THERAPY, 2021, 29 (03) : 989 - 1000
  • [36] AAV9 Mediated Dars2 Gene Therapy Prevents Neurodegeneration in Two Mouse Models of LBSL
    Garofolo, Ines L.
    Liang, Yajie
    Janowski, Miroslaw
    Walczak, Piotr
    Fatemi, Ali
    Nemeth, Christina L.
    MOLECULAR THERAPY, 2024, 32 (04) : 702 - 702
  • [37] CNS-Directed AAV9 Gene Therapy for the Treatment of Canine Globoid Cell Leukodystrophy (Krabbe Disease)
    Bradbury, Allison M.
    Bagel, Jessica H.
    Hendricks, Ian J.
    Duc Nguyen
    Bongarzone, Ernesto R.
    Gray, Steven J.
    Vite, Charles H.
    MOLECULAR THERAPY, 2019, 27 (04) : 189 - 189
  • [38] Optimization of Systemic AAV9 Gene Therapy in Niemann-Pick Type C1 Mice
    Mylvara, Avani
    Davidson, Cristin
    Gu, Tansy
    Gibson, Alana L.
    Baxter, Laura
    Incao, Art
    Venditti, Charles P.
    Pavan, William
    Porter, Forbes D.
    MOLECULAR THERAPY, 2024, 32 (04) : 732 - 732
  • [39] Amyotrophic Lateral Sclerosis gene therapy using recombinant AAV9 vectors to silence the mutant SOD1 gene
    Biferi, M. G.
    Roda, M.
    Barkats, M.
    HUMAN GENE THERAPY, 2012, 23 (05) : A17 - A17
  • [40] Tyrosine Mutation in AAV9 Capsid Improves Gene Transfer to the Mouse Lung
    Martini, Sabrina V.
    Silva, Adriana L.
    Ferreira, Debora
    Rabelo, Rafael
    Ornellas, Felipe M.
    Gomes, Karina
    Rocco, Patricia R. M.
    Petrs-Silva, Hilda
    Morales, Marcelo M.
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016, 39 (02) : 544 - 553
12345